Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, single-arm, real-world trial is designed to assess the safety and efficacy of DEXTENZA for the treatment of ocular inflammation and pain following cataract surgery

Next Previous
Trial Profile

A prospective, single-arm, real-world trial is designed to assess the safety and efficacy of DEXTENZA for the treatment of ocular inflammation and pain following cataract surgery

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Ocular inflammation; Ocular pain
  • Focus Therapeutic Use

Most Recent Events

  • 31 Oct 2023 Primary endpoint Absence of anterior chamber cells in the study eye at Day 14 has been met, according to an AffaMed Therapeutics media release.
  • 31 Oct 2023 According to a AffaMed Therapeutics media release, this trial was conducted in the Boao Lecheng Pilot Zone in Hainan, China.
  • 31 Oct 2023 Positive top-line results presented in an AffaMed Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top